As filed with the Securities and Exchange Commission on August 11, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
EVOKE PHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
|
| 20-8447886 |
(State or Other Jurisdiction of Incorporation or Organization) |
|
|
| (I.R.S. Employer Identification No.) |
|
| 420 Stevens Avenue, Suite 370 Solana Beach, CA 92075 (858) 345-1494 |
|
|
|
| (Address of Principal Executive Offices) |
|
|
EVOKE PHARMA, INC. 2013 EQUITY INCENTIVE AWARD PLAN
EVOKE PHARMA, INC. 2013 Employee Stock Purchase Plan
(Full Title of the Plan)
David A. Gonyer, R.Ph.
Chief Executive Officer
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 370
Solana Beach, CA 92075
(858) 345-1494
Copy to:
Cheston J. Larson, Esq.
Matthew T. Bush, Esq.
Anthony Gostanian, Esq.
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, CA 92130
(858) 523-5400
(Name, Address and Telephone Number, Including Area Code, of Agent for Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
| ☐ |
| Accelerated filer |
| ☐ | |
|
|
|
| ||||
Non-accelerated filer |
| ☒ |
| Smaller reporting company |
| ☒ | |
|
|
|
|
|
|
| |
|
|
|
| Emerging growth company |
| ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This registration statement on Form S-8 (the “Registration Statement”) registers the offer and sale of an additional 810,000 shares of our common stock under the Evoke Pharma, Inc. 2013 Equity Incentive Award Plan (as amended and restated, the “2013 Plan”) and an additional 170,000 shares of our common stock under the Evoke Pharma, Inc. 2013 Employee Stock Purchase Plan (as amended and restated, the “ESPP”). In accordance with Instruction E to Form S-8, the contents of the prior registration statements (File Nos. 333-191518, 333-211302, 333-219960, and 333-224897) are hereby incorporated by reference.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The document(s) containing the information specified in Part I will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Securities and Exchange Commission (the “SEC”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
In this Registration Statement, Evoke Pharma, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”
Item 3. Incorporation of Documents by Reference.
The SEC allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:
All documents that we subsequently file pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to the Registration Statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under Item 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Under no circumstances will any information furnished
under Item 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.
You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. We have not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.
Item 8. Exhibits.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Number |
| Exhibit Description |
| Incorporated by Reference |
| Filed |
| |||||||||||||||
|
| Form |
| File No. |
|
| Exhibit |
|
| Filing Date |
|
| ||||||||||
|
|
|
|
|
|
|
| |||||||||||||||
3.1 |
|
| 8-K |
|
| 001-36003 |
|
|
| 3.1 |
|
| 9/30/2013 |
|
| |||||||
|
|
|
|
|
|
|
| |||||||||||||||
3.2 |
| Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company |
| 8-K |
|
| 001-36075 |
|
|
| 3.1 |
|
| 5/20/2022 |
|
| ||||||
|
|
|
|
|
|
|
| |||||||||||||||
3.3 |
|
| 8-K |
|
| 001-36003 |
|
|
| 3.2 |
|
| 9/30/2013 |
|
| |||||||
|
|
|
|
|
|
|
| |||||||||||||||
4.3 |
|
| S-1/A |
|
| 333-188838 |
|
|
| 4.1 |
|
| 8/16/2013 |
|
| |||||||
|
|
|
|
|
|
|
| |||||||||||||||
5.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| X | |||||||
|
|
|
|
|
|
|
| |||||||||||||||
10.1 |
| Evoke Pharma, Inc. 2013 Equity Incentive Award Plan, as amended and restated effective May 10, 2023 |
| DEF 14A |
|
| 001-36075 |
|
|
| Appendix A |
|
| 3/29/2023 |
|
| ||||||
10.2 |
| Evoke Pharma, Inc. 2013 Employee Stock Purchase Plan, as amended and restated effective May 10, 2023 |
| DEF 14A |
|
| 001-36075 |
|
|
| Appendix B |
|
| 3/29/2023 |
|
| ||||||
|
|
|
|
|
|
|
| |||||||||||||||
23.1 |
| Consent of BDO USA, LLP, independent registered public accounting firm |
|
|
|
|
|
|
|
|
|
|
|
|
| X | ||||||
|
|
|
|
|
|
|
| |||||||||||||||
23.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| X | |||||||
|
|
|
|
|
|
|
| |||||||||||||||
24.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| X | |||||||
107.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| X |
Item 9. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement;
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement;
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Solana Beach, State of California, on August 11, 2023.
|
|
|
EVOKE PHARMA, INC. | ||
|
| |
By: |
| /s/ David A. Gonyer |
|
| David A. Gonyer, R.Ph. |
|
| Chief Executive Officer and Director |
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints David A. Gonyer, R.Ph. and Matthew J. D’Onofrio, jointly and severally, his attorneys-in-fact, each with the full power of substitution, for him in any and all capacities, to sign this Registration Statement, and any amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Signature |
| Title |
| Date |
|
|
| ||
|
|
| ||
/s/ David A. Gonyer |
| Chief Executive Officer and Director (Principal Executive Officer) |
| August 11, 2023 |
David A. Gonyer, R.Ph. |
|
| ||
|
|
| ||
/s/ Matthew J. D’Onofrio |
| President, Chief Operating Officer, Secretary and Treasurer (Principal Financial and Accounting Officer) |
| August 11, 2023 |
Matthew J. D’Onofrio |
|
| ||
|
|
| ||
/s/ Cam L. Garner |
| Chairman of the Board of Directors |
| August 11, 2023 |
Cam L. Garner |
|
| ||
|
|
| ||
/s/ Todd C. Brady |
| Director |
| August 11, 2023 |
Todd C. Brady, M.D., Ph.D. |
|
| ||
|
|
| ||
/s/ Malcolm R. Hill |
| Director |
| August 11, 2023 |
Malcolm R. Hill, Pharm.D. |
|
| ||
|
|
| ||
/s/ Vickie W. Reed |
| Director |
| August 11, 2023 |
Vickie W. Reed |
|
| ||
|
|
| ||
/s/ Kenneth J. Widder |
| Director |
| August 11, 2023 |
Kenneth J. Widder, M.D. |
|
|